Joy, Share Price & Revenue@Gonefishing, if my memory serves correctly (please someone do correct me if I recall this incorrectly) once we attain Accelerated Approval status then we may begin to charge for the procedure. If that's true and revenue begins to flow before full FDA approval, then the share price moves. I think if/when we receive AA the BigPharma bids will get serious.
However, I still think RDM will not sell 100% of the company to include all indications and patents. I think the plan is to license by indication to get the most value for as many pieces as the company can negotiate. That's what I would try first. BigPharma may dictate an all-or-none condition. I'd say no, b/c if we sell to BigPharma then they would license by indication and we wouldn't benefit on future success. An all-or-none with cash buyout and stock would permit shareholders (RDM/KH et al) to participate in any future success from the suitor. It also permits any shareholder to execute a sale at their choosing.
I can only imagine the joy a patient and their Urooncologist would experience once this drug becomes available. Not only to the BCG negative, but those patients that are diagnosed early and will not have to experience the multiple procedures. Thinking of you Goose.
My hopes for all cancer patients, their families and the good Dr's trying to same them.
Good Luck To All.
Regards, BK